MERIT acquires OSOD to aid in early stage drug development

Image credit: AdobeStock/Panumas

Global clinical trial endpoint and technology services provider MERIT announced that the company has acquired Ocular Services On Demand (OSOD), a consortium of vision science and ocular development experts.¹ According to a news release, the acquisition was completed with the goal of enhancing MERIT’s service offerings and allowing for successful transitions from preclinical to clinical phases of drug development.

“MERIT is delighted to welcome OSOD to our family. This acquisition represents a significant milestone in our mission to advance drug development and deliver life-changing therapies to patients worldwide,” said Yijun Huang, CEO of MERIT, in the release. “Together, we will set new standards in the industry and drive forward the future of medicine.”

OSOD has operated for over 30 years in ophthalmic preclinical drug development, having influenced the advancements of several ophthalmic therapies from preclinical research to market approval. A handful of those therapies include Lucentis, Eylea, Xiidra, Susvimo, and Durysta.¹

“OSOD has always been committed to excellence in early-stage ophthalmology research. Joining forces with MERIT allows us to extend our impact and contribute to the entire drug development continuum,” said Christopher Murphy, CEO of OSOD, in the release. “Importantly, the entire management team, employees and our distributed network of experts in vision science and drug development remain committed to advancing the impact of OSOD in ocular drug development. We look forward to leveraging the resources and capabilities of MERIT to the benefit of our clients in bringing much needed therapeutics to the marketplace to benefit patients. We look forward to a collaborative and innovative future.”

Reference:

1. MERIT acquires OSOD, expanding capabilities in early-stage drug development. News release. January 22, 2025. Accessed January 22, 2025. https://meritcro.com/news/merit-acquires-osod-expanding-capabilities-in-early-stage-drug-development/